Dividendos de Merck

Dividendo controles de criterios 4/6

Merck es una empresa que paga dividendos con una rentabilidad actual de 2.36%.

Información clave

2.3%

Rentabilidad por dividendo

325%

Ratio de pago

Rentabilidad media de la industria	2.4%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	US$0.91
Rentabilidad por dividendo prevista a 3 años	2.6%

Últimas actualizaciones de dividendos

Recent updates

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

Dec 25

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: Los dividendos por acción de MRK se han mantenido estables en los últimos 10 años.

Dividendo creciente: El pago de dividendos de MRK ha aumentado en los últimos 10 años.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Merck vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de MRK con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (MRK)	2.3%
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.8%
Media de la industria (Pharmaceuticals)	2.4%
Previsión de analistas en 3 años (MRK)	2.6%

Dividendo destacado: El dividendo de MRK(2.36%) es más alto que el 25% inferior de los pagadores de dividendos del mercado US (1.54%).

Alto dividendo: El (2.36%) del dividendo de MRK es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado US (4.7%).

Pago de beneficios a los accionistas

Cobertura de los beneficios: Con su elevado ratio de pago (240.8%), los pagos de dividendos de MRK no están bien cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Con su actual ratio de pago en efectivo (85.3%), los pagos de dividendos de MRK están cubiertos por los flujos de caja.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de Merck

Dividendo controles de criterios 4/6

Información clave

Últimas actualizaciones de dividendos

Upcoming dividend of US$0.77 per share

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Recent updates

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck's Future Brightens With Winrevair's Blockbuster Potential

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck: A High-Conviction Investment For Long-Term Growth

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Insider notifies of intention to sell stock

Insider exercised options and sold US$1.7m worth of stock

Executive VP & General Counsel recently sold US$3.8m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 16%

Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Third quarter dividend of US$0.77 announced

Is Merck & Co., Inc. (NYSE:MRK) Trading At A 47% Discount?

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies